| Document |
Document Title |
|
WO/2010/123016 |
Disclosed is a compound having a GPR40 agonistic activity and useful for use in a pharmaceutical composition or useful as an insulin secretion promoter or a prophylactic or therapeutic agent for diabetes. Extensive studies have been made...
|
|
WO/2010/122799 |
Disclosed is an aromatic amine derivative represented by formula (1). (In the formula, A1 represents an alkyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heterocyclic ring group, or an organic gro...
|
|
WO/2010/123139 |
Disclosed is a long-chain fatty acid elongase (Elovl6) inhibitor, which is characterized by comprising at least one of a compound represented by formula (I), a pharmaceutically acceptable salt of the compound, and a solvate of the compou...
|
|
WO/2010/118598 |
The crystal form A of furanodiene which characteristic peaks at 2θ of 11.4°(±0.1°), 13.4°(±0.1°), 15.3°(±0.1°), 19.6°(±0.1°) and 24.6°(±0.1°) in x-ray powder diffraction pattern. This crystal has the absorption peak at 69...
|
|
WO/2010/121226 |
The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described.
|
|
WO/2010/121226 |
The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described.
|
|
WO/2010/115952 |
The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a p...
|
|
WO/2010/115897 |
The present invention relates in general to the field of organic chemistry and in particular to the preparation of 1-(2,3-dihydrobenzofuran-4-yl)ethanone, an intermediate in preparation of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]fu...
|
|
WO/2010/116140 |
There is provided a process for the preparation of a compound of formula (II), wherein R1, R2, R3 and R4 are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dron...
|
|
WO/2010/115897 |
The present invention relates in general to the field of organic chemistry and in particular to the preparation of 1-(2,3-dihydrobenzofuran-4-yl)ethanone, an intermediate in preparation of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]fu...
|
|
WO/2010/117986 |
A process is provided for the synthesis of tetrahydrofuran and related compounds by hydrogenation of furan and derivatives, using a sponge nickel catalyst that has been promoted with iron and chromium.
|
|
WO/2010/117040 |
Disclosed is a compound having excellent FATP4 inhibitory activity. Specifically disclosed is a five-membered heterocyclic compound represented by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), A represents -C...
|
|
WO/2010/116140 |
There is provided a process for the preparation of a compound of formula (II), wherein R1, R2, R3 and R4 are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dron...
|
|
WO/2010/113831 |
Disclosed are a method which can produce a chemical compound precursor body for a light-emitting element material which is difficult to produce using conventional methods, and a method for therefrom producing a suitable material and an o...
|
|
WO/2010/113725 |
Disclosed is a novel compound derived from the culture of an actinomycete and having an anti-tumor activity. Specifically disclosed is a compound represented by formula (I), (II), or (III), an optical isomer thereof, or a pharmaceuticall...
|
|
WO/2010/112211 |
The present invention relates to a method for producing biphenyl compounds substituted in the ring. The method can be performed in a cost-effective manner and provides good regioselectivity. Functionalized biphenyl compounds are of great...
|
|
WO/2010/113022 |
Provided are a novel compound which exhibits a plasminogen activator inhibitor-1 (PAI-1) inhibiting activity, a PAI-1 inhibitor which comprises said compound as an active component; and a pharmaceutical composition which comprises the co...
|
|
WO/2010/091185 |
|
|
WO/2010/108584 |
The present invention relates to a process for preparing N-substituted furan-2(5H)-ones where the reaction medium comprises at least one Ionic Liquid, to the use of Ionic Liquids for preparing furan-2(5H)-ones, and to compounds preparabl...
|
|
WO/2010/110646 |
The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with a phosphodiesterase (PDE) dependent disease or condition of the central nervous s...
|
|
WO/2010/110646 |
|
|
WO/2010/110647 |
|
|
WO/2010/105930 |
The present invention relates to new carbamate derivatives of formula I, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders, such as neuropathic pain and anxiety.
|
|
WO/2010/106053 |
A process is disclosed for converting a polysaccharide-containing biomass material to platform chemicals. The process comprises dissolving the polysaccharides in an inorganic molten salt hydrate, converting the polysaccharides to monosac...
|
|
WO/2010/105772 |
The invention relates to a method for producing enaminocarbonyl compounds. In said method, compounds of formula (II) are reacted with compounds of formula (III), in which the groups A, R1, R2 and Z are defined as cited in the description...
|
|
WO/2010/105772 |
The invention relates to a method for producing enaminocarbonyl compounds. In said method, compounds of formula (II) are reacted with compounds of formula (III), in which the groups A, R1, R2 and Z are defined as cited in the description...
|
|
WO/2010/103553 |
A process is described for the preparation on an industrial scale of N-[2-(8S)- 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl] propionamide, ramelteon, having the structure illustrated below: (I).
|
|
WO/2010/104722 |
Processes for producing formic acid from a carbohydrate-containing material include hydrolyzing a carbohydrate-containing material (e.g., cellulose) in the presence of a mineral acid to form an intermediate hydrolysate comprising one or ...
|
|
WO/2010/103976 |
Phthalic acid was dehydrated in heptane with heating/refluxing in the presence of a catalytic amount of an arylboronic acid compound (e.g., 2-(diisopropylaminomethyl)phenylboronic acid or 2,6-bis(diisopropylaminomethyl)phenylboronic acid...
|
|
WO/2010/104738 |
The invention provides an improved method of synthesizing chemicals according to the ene reaction. The method addresses two problems that previously could not be addressed simultaneously, preventing charring of the reaction, and preventi...
|
|
WO/2010/102758 |
The invention relates to novel compounds of formula (I), wherein W, X, Y, Z and CKE are defined as indicated above, to several methods and intermediates for producing the same and to their use as pest control agents and/or herbicides. Th...
|
|
WO/2010/102848 |
Compounds of Formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2010/104194 |
The present invention provides a compound represented by the following formula (I): wherein: Ring A represents an optionally substituted piperazine ring, an optionally substituted morpholine ring, or an optionally substituted bomopiperaz...
|
|
WO/2010/102758 |
The invention relates to novel compounds of formula (I), wherein W, X, Y, Z and CKE are defined as indicated above, to several methods and intermediates for producing the same and to their use as pest control agents and/or herbicides. Th...
|
|
WO/2010/101024 |
The purpose of the present invention is to provide a method for preparing 5-hydroxymethylfurfural (HMF) from a saccharide at a low cost under mild conditions. Attention has been paid to a reaction path for the preparation of HMF from a s...
|
|
WO/2010/098193 |
Optically active β-aminocarbonyl compounds are obtained by a Mannich reaction of an optically active binaphthol represented by formula (1a), (1b), (2a) or (2b) (in each formula, Ar1 is a phenyl group wherein hydrogen atoms are bound to ...
|
|
WO/2010/097374 |
The invention relates to the compounds of the general formula (I) wherein n, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as described in the description, to enantiomers thereof, to diastereomers thereof, to mixtures and salts thereof, ...
|
|
WO/2010/094090 |
Present inventions demonstrates that NHE-1 inhibiting carbonylguanidine derivatives inhibit α-synuclein toxicity. Such compounds can be used in the treatment or prevention of synucleinopathies, such as Parkinson's disease (PD), dementia...
|
|
WO/2010/094242 |
The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alz...
|
|
WO/2010/094659 |
The invention relates to the use of compounds of formula (I), wherein the substituents are described in the description and claims, for the preparation of medicaments for the treatment of psychoses, dysfunction in memory and learning, sc...
|
|
WO/2010/094090 |
Present inventions demonstrates that NHE-1 inhibiting carbonylguanidine derivatives inhibit α-synuclein toxicity. Such compounds can be used in the treatment or prevention of synucleinopathies, such as Parkinson's disease (PD), dementia...
|
|
WO/2010/092107 |
The present invention relates in general to the field of organic chemistry and in particular to the preparation of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)eth
yl]propionamide, i.e. ramelteon, and analogues thereof.
|
|
WO/2010/092153 |
The invention relates to substituted tetrahydronapthalenes, to derivatives thereof, to physiologically acceptable salts thereof, to physiologically functional derivatives, to the production thereof, to drugs containing at least one subst...
|
|
WO/2010/092154 |
The invention relates to substituted indanes and derivatives thereof, to physiologically acceptable salts and physiologically functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane ...
|
|
WO/2010/093021 |
Disclosed is a polyesterimide having a repeating unit represented by formula (3), which has a high glass transition temperature, a linear expansion coefficient equal to or lower than that of a metal foil, an extremely low water absorptio...
|
|
WO/2010/092872 |
The present invention relates to a process for producing (±)-3a,6,6,9a-tetramethyl dodecahydronaphtho[2,l-b]furans from crude (±)-3a,6,6,9a-tetramethyl dodecahydronaphtho[2,l-b]furans obtained by subjecting (±)-3a,6,6,9a-tetramethyl d...
|
|
WO/2010/092872 |
The present invention relates to a process for producing (±)-3a,6,6,9a-tetramethyl dodecahydronaphtho[2,l-b]furans from crude (±)-3a,6,6,9a-tetramethyl dodecahydronaphtho[2,l-b]furans obtained by subjecting (±)-3a,6,6,9a-tetramethyl d...
|
|
WO/2010/091193 |
Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.
|
|
WO/2010/091193 |
Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.
|
|
WO/2010/091384 |
Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.
|
